17518-48-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Chlorophenyl)thioacetamide is utilized as a pharmaceutical intermediate, playing a crucial role in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to serve as a building block for the development of new drugs with potential therapeutic applications.
As a pharmaceutical intermediate, 2-(4-Chlorophenyl)thioacetamide is used for the following reasons:
1. Its chemical structure can be modified to create a wide range of pharmaceutical compounds with different therapeutic properties.
2. The presence of the chlorophenyl group provides opportunities for further functionalization and diversification of the molecule.
3. The thioketone functional group can be involved in various chemical reactions, enabling the synthesis of complex drug molecules.

InChI:InChI=1/C8H8ClNS/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4H,5H2,(H2,10,11)

Upstream product

• 99-91-2 para-chloroacetophenone 
• 7783-06-4 hydrogen sulfide 
• 141-52-6 sodium ethanolate 
• 140-53-4 p-chlorobenzyl cyanide 
• 1878-66-6 4-chlorophenylacetic Acid 
• 20101-92-2 2-(4-chlorophenyl)acetamide 
• 25026-34-0 4-chlorophenacetyl chloride 

Downstream Products

• 25021-50-5 4-[2-(4-chloro-benzyl)-thiazol-4-yl]-aniline 
• 25020-91-1 2-(4-chloro-benzyl)-5-methyl-4-phenyl-thiazole 
• 1214888-56-8 C₁₉H₁₆ClNO₃S 
• 1214888-54-6 C₁₈H₁₄ClNO₂S 
• 1214888-55-7 C₁₈H₁₃Cl₂NO₂S 
• 1214888-60-4 [2-(4-chlorobenzyl)-4-(4-phenoxy-phenyl)-thiazol-5-yl]acetic acid 
• 1200399-90-1 N-{2-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazol-5-yl}-1,2,3,4-tetrahydro-6-isoquinolinecarboxamide hydrochloride 
• 1200399-48-9 1,1-dimethylethyl 6-[({2-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazol-5-yl}amino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1200399-46-7 1,1-dimethylethyl {2-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazol-5-yl}carbamate 
• 938001-17-3 2-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxylic acid 
• 1200399-45-6 ethyl 2-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxylate 
• 6437-55-4 N-(2-3'-methylphenoxypropyl)-4-chlorophenylacetamidine p-toluenesulphonate 

Relevant academic research and scientific papers

Phosphorus pentasulfide: A mild and versatile reagent for the preparation of thioamides from nitriles

A simple, efficient, and new method has been developed for the synthesis of thioamides from nitriles. The reaction of a variety of aromatic and aliphatic nitriles in the presence of phosphorus pentasulfide afforded the corresponding thioamides in high yields. This method is easy, rapid, and high-yielding for the synthesis of thioamides from nitriles. Georg Thieme Verlag Stuttgart.

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

PYRROLIDINE DERIVATIVES AS INHIBITOR OF FIBROBLAST ACTIVATION PROTEIN (FAP) AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME

The FAP inhibitor is represented by the following formula X. The present invention relates to a pyrrolidine derivative or a pharmaceutically acceptable salt thereof. Chem. X.

Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1

Structure-activity relationships of three related series of 4-phenylthiazol-5-ylacetic acids, derived from two hits emanating from a focused library obtained by in silico screening, have been explored as CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) antagonists. Several compounds with double digit nanomolar binding affinity and full antagonistic efficacy for human CRTH2 receptor were obtained in all subclasses. The most potent compound was [2-(4-chloro-benzyl)-4-(4-phenoxy-phenyl)-thiazol-5-yl]acetic acid having an binding affinity of 3.7 nM and functional antagonistic effect of 66 nM in a BRET and 12 nM in a cAMP assay with no functional activity for the other PGD2 DP receptor (27 μM in cAMP).